Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans

Cardiovascular Therapeutics

Volumn 30, Issue 1, 2012, Pages 5-11

  Park, Kyung Woo ^a   Park, Jin Joo ^a   Jeon, Ki Hyun ^a   Kang, Si Hyuk ^a   Oh, Il Young ^a   Yang, Han Mo ^a   Cho, Hyun Jai ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Clinical predictors; Clopidogrel; High posttreatment platelet reactivity; Inter racial difference; Korean

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DETERMINATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KOREA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEX RATIO; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; KIDNEY DISEASES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84863012104     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00249.x     Document Type: Article

References (27)

1. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
2. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425.
3. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832.
4. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
5. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
6. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339-1343.
7. Shuldiner A, O'Connell J, Bliden K, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-857.
8. Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7:897-899.
9. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315-322.
10. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-284.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-2560.
12. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
13. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-533.
14. Berger J, Bhatt D, Steinhubl S, et al. Smoking, Clopidogrel, and mortality in patients with established Cardiovascular disease. Circulation 2009;120:2337-2344.
15. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-449.
16. Ghotbi R, Christensen M, Roh H, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007;63:537-546.
17. Zhou S, Yang L, Zhou Z, Liu Y, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of Human Cytochrome P450 1A2. AAPS J 2009;11:481-494.
18. Siller-Matula J, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-1563.
19. Lau W, Waskell L, Watkins P, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation a new drug-drug interaction. Circulation 2003;107:32-37.
20. Gurbel P, Lau W, Tantry U. Omeprazole a possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;51:261-263.
21. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509.
22. Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009;102:719-727.
23. Bisoendial RJ, Kastelein JJ, Peters SL, et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007;48:952-960.
24. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001;98:2720-2725.
25. Cohen Arazi H, Doiny DG, Spampinato Torcivia R, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turn-over in cardiac surgery. Interact Cardiovasc Thorac Surg 2010;10:863-867.
26. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
27. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 2008;4:413-424.